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Talpra magyar, hı´ a haza !
Itt az ido˜, most vagy soha !
Rabok legyu¨nk, vagy szabadok ?
Ez a ke´rde´s, va´lasszatok !
A magyarok istene´re
Esku¨szu¨nk,
Esku¨szu¨nk, hogy rabok tova´bb
Nem leszu¨nk !
Rise up, Magyar, the country calls!
It_s Fnow or never_ what fate befalls...
Shall we live as slaves or free men?
That_s the question - choose your FAmen_!
God of Hungarians,
we swear unto Thee,
We swear unto Thee - that slaves we shall
no longer be!
- Sandor Peto¨fi, Hungarian Poet, 1823–1849
In this journal, Scuffham & Ko´sa present a cost-
effectiveness analysis of the statin fluvastatin in
patients following successful percutaneous coronary
interventions [1]. The country of reference for this
analysis was Hungary, a country which had a more
than 40 years experience with a communistic regime,
undergoing major transformations in the healthcare
system. Recently, the country has joined the European
Union. Economic thinking was slowly changing in
order to adopt a new more liberal and more open,
market-driven system. Economic thinking in health
care is reaching a turning point and issues of resource
allocation and prioritization are reaching a new
dimension gaining increasing central attention. In this
stage of development, economic analyses of health
care technologies and health care technology assess-
ment have become an important area of interest. Thus,
we may applaud the Hungarians for yielding an
increasing number of such interventions, such as the
present study by Scuffham & Kosa.
When scholars such as me occasionally get asked by
editors-in-chief of scientific journals to write an
editorial on an original piece of work, I usually
encounter three distinct situations. First, I might
realise that the paper to be discussed is a kind of
paper which cannot be understood without the accom-
panying, clarifiying and educating comments of an
expert. Second, I might feel that the paper is of such
controversial content, that the editor (and the readers
too) require a balanced counter-argumentation of the
findings and the conclusions. Third, the paper may
exert high quality, be well-conducted, according to
international guidelines for economic analyses in
health care, convey a balanced view and, to a great
deal, speak for itself. In this instance an editorial
would clearly be superfluous. I felt that I stood in front
of the latter situation. So, what to do? Somehow I did
not want to disappoint my editor-in-chief and felt
obliged to obey by deciding to write on three topics.
First, the health of Hungarians is currently and has not
always been in great shape. I needed to discuss this
situation and focus on cardiovascular health. This is
important for local cardiovascular public health policy
makers. Second, I wanted to present some highlights
on the Hungarian health system and the utilisation of
interventional cardiovascular procedures. This is im-
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portant for health care providers. Third, economic
analyses in Hungary are fairly new and deserve their
place in the system. I wanted to discuss their increas-
ingly important role. This is important for health
economists. Last, but not least, having had a Hungar-
ian father myself, who conveyed to me the love to the
people and products of his home country, I felt obliged
and honoured to put my thoughts to paper. Hence, I
confirmed to my editor-in-chief.
The health of Hungarians
While the system resembling many of its broad
features those of other OECD countries, Hungarians
have the lowest life expectancy in the OECD and its
rate of increase over the last 20 years has been much
slower than in the rest of the area [2]. (Table 1).
Between 1930 and 1960 life expectancy at birth rose by
more than 20 years in many OECD countries, as it did
in Hungary. Since then, progress has been less rapid,
with life expectancy increasing by 8.7 years between
1960 and 1990 in the OECD area but only 1.3 years in
Hungary; and male life expectancy has actually been
falling. As a result, Hungary now has the lowest life
expectancy in the area. Outcomes are poor for all age-
sex groupings but especially for males between 40 and
60 years of age, whose total life expectancy of 68.8
years is seven years less than the OECD average of
75.9 years and is lower than it was in 1930. Female life
expectancy is also the lowest among OECD countries,
although it has been rising, and is much higher than for
males, the gap between them having more than
doubled from 4.4 to 9.1 years between 1960 and 1998.
Although it is too soon to know if it represents a
temporary improvement or a new positive long-term
trend, since 1995 the life expectancy at birth of males
has started to increase.
Over-work, poor diet, alcohol and tobacco addic-
tion, unfulfilling work, falls in relative income and
growing income inequalities, as well as feelings of
relative disadvantage compared with western Europe
are considered to be the principal factors contributing
to high prime-age male mortality both now and in the
1970s and 1980s. Alcoholism has been cited as an
important source of Hungarian mortality and Hungary
has the third highest consumption rates in the OECD.
The incidence of smoking is also high; 44 per cent of
men and 27 per cent of women smoke (the fifth and
eighth highest rates in the OECD). Spending on
alcohol and tobacco products represent about twenty
per cent of total food expenditures with the poorest 10
per cent of the population spending as much as 7.3 per
cent of their income on these products. Although total
caloric intake per capita is around the OECD average,
the traditional Hungarian diet relies excessively on
foods with a high fat and sugar content, both of which
constitute serious health hazards. Deaths per capita
from associated diseases exceed OECD averages by a
wide margin, with Hungarians having the highest
mortality rates in the area for cancers of the respira-
tory tract, heart diseases and cirrhosis of the liver.
(Table 2).
Table 1 Key data on Hungarian health care system 2003
Variable Hungary Poland Czech Republic Slovakia Germany UK
Age >65 years (%) 15.4 12.9 13.9 11.5 17.7 16
Life expectancy at birth (years) 72.4 74.7 75.3 73.9a 78.4 78.5
Acute beds/1000 inhabitants (n) 5.9 5.1 6.5 5.9 6.6a 3.7
Acute beds, occupancy rates (%) 77.2 77.0a 73.9 65.4 80.1a 85.1
Average length of stay, acute (days) 8.4 7.9a 10.9 8.7 10.9a 8.1
THCE, % of GDP 7.8a 6.0a 7.5 5.9 11.1 7.7a
THCE per capita,US$ PPP 1115a 677 1298 777 2996 2231a
Alcohol consumption (l/day) 13.4a 8.1a 12.1 7.6 10.2 11.2
Calories/db 3483 3375 3171 2889 3496 3412
% of population >15 yrs, smoking 33.8 27.6b 24.1a 24.3 24.3 26.0
BMI>25 52.8 n/a 51.1a 57.6a 49.2 62c
a 2002
b 2001
c different methodology
GDP: Gross domestic product
THCE: totla health care expenditure
PPP: purchasing parity index
BMI: body mass index in kg/m2
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Key features of the Hungarian health care system
The Hungarian health system is relatively resource
intensive and is characterised by high hospitalisation
rates, an excess supply of specialists and perverse
incentives both for doctors and hospital administrators.
Budgetary rules prevent hospitals from properly amor-
tising investments and limit their capacity to manage
labour costs. Furthermore inadequate supervision of
billing by the state administrator has led to a fraudu-
lent inflation in both the number and the Bseriousness^
of treatments. Recent reforms have concentrated on
containing costs but efforts to improve service delivery
and health outcomes have been plagued by problems
of institutional conflict. Although cost pressures on the
healthcare system are likely to intensify in the future,
the economy_s capacity to pay will improve and, as a
result, the gap between the quality and quantity of
Hungarian versus European healthcare will gradually
close.
Hungary has a comprehensive insurance-type health
care system, based on the principle of social solidarity.
Accordingly, compulsory contributions by employees
are paid according to earnings, rather than individuals_
health risks. Coverage is close to universal in terms of
treatments provided, with virtually all citizens benefit-
ing from the service whether they contribute or not.
Within this context, however, the system is now
radically different from that in place at the beginning
of the 1990s, a reflection of the wide ranging structural
reforms introduced. In particular, it is no longer as
strongly integrated in the state sector and operates
under a purchaser-provider approach.
Hungary_s measured expenditures on healthcare
are, as a share of GDP, among the lowest in the
OECD. In absolute terms, its spending is 7.8 of the
gross domestic product and is about half the level of
Spain and Portugal and only 38 per cent of the OECD
average. In terms of per capita public expenditures,
relative position of Hungary has worsened both
compared to the OECD average and to the less
developed OECD countries. In this context, the
increase in pharmaceutical expenditures has been
considered a major health policy problem. However,
data show that the observed spending pattern is not
that different from that observed in other lower
income OECD countries and is converging to this
norm.
One area where spending discipline will become
increasingly important in Hungary is health care.
Reforms need to consider ways to make financing
more stable and sustainable. The slow progress in
modernising the health care system is reflected in the
low efficiency of hospitals, excessive recourse to
inpatient care and heavy prescription of drugs by
doctors.
Eastern European transitional countries have the
highest mortality rates from cardiovascular diseases in
Europe. In 2001, the standardized death rates (per
100,000 inhabitants) from cardiovascular diseases for
men and women aged 0–64 were 212.1 in Ukraine,
176.0 in Bulgaria, and 149.8 in Romania. In contrast,
these death rates were the lowest in economically
stable countries, such as France, Spain, and the
Netherlands (31.2, 35.4, and 41.6 per 100,000 inhab-
itants [3]. In Hungary, the standardized cardiovascular
death rate was 175 per 100,000 in 1991 and 121 per
100,000 in 2003. The corresponding figures for Europe
were 117 and 122. In ischemic heart disease, the
standardized death rates in Hungary were 85/100,000
in 1991 and 59/100,000 in 2003. The corresponding
figures across Europe were 81 and 80.
Since the first percutaneous transluminal coronary
angioplasty (PTCA) performed in 1977, the number of
PCIs has increased dramatically, with more than
733,000 now performed annually in Europe [4]. The
mean population-adjusted rate in 2003 was 1283
procedures per 106 inhabitants, which is a 5% increase
from 2002. Germany reported the highest number
(2522/106 inhabitants) whereas Romania reported the
lowest number (152/106 inhabitants). The highest
relative increases were observed in Greece (+70%),
Slovakia (+50%), Poland (+50% and Hungary
(+46%). About 35% of all PCI uses drug eluting
stents. Table 2 and Fig. 1 give an overview of key
indicators of interventional cardiology and their de-
velopment in Hungary and in comparison to other
countries.
Table 2 Key indicators of interventional cardiology
Indicator Hungary Poland Czech Republic Slovakia Germany UK
Coronary angiograms/106 inhabitants [7] 1651 1393 2971 1047 7344 2544
PTCAs/106 inhabitants 251 504 927 193 2226 590
Drug eluting stent rate (%) 35 45 36 27 32 29
PCIs per angiogram ratio 0.15 0.36 0.31 0.18 0.3 0.23
Stenting/PTCA 0.79 0.44 0.66 0.51 0.68 0.8
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What did the LIPS study show and what can we learn
from health economics?
The LIPS study is the first prospective trial in patients
undergoing their first PCI with clinical outcomes as the
primary end point [5]. Patients enrolled in our study
generally had an earlier CHD stage (all had unstable
or stable angina or silent ischemia, and less than half
had prior MI) and statin therapy was initiated very
early after the index procedure compared with earlier
trials. Results of the LIPS study show that in patients
with average cholesterol levels, early cholesterol-
lowering treatment with fluvastatin, 80 mg/d, following
first PCI with or without stenting resulted in a 5.3%
absolute reduction and a 22% relative reduction in the
risk of fatal or nonfatal major adverse cardiac events
during 4 years of follow-up compared with placebo.
These results suggest that treating 19 post-PCI patients
with fluvastatin for 4 years would prevent 1 fatal or
nonfatal MACE (number needed to treat, 19; 95% CI,
11–82), suggesting benefit similar to that observed in
other secondary prevention trials.
Prevention of restenosis and cardiac events in
patients who have had percutaneous revascularization
is of enormous public health importance. Substantial
amounts of effort and monies have been spent on
multiple drug strategies, but with limited success.
The fundamental aim of any health care system is to
maximize the health and welfare of its population, but
because resources will always be scarce in relation to
the health care needs, a series of choices must be
made. Decision makers responsible for allocating
resources need to prioritize between competing uses
in order to maximize benefits (or health gains) under
budgetary constraints. Prioritization takes place on
different levels of the health care system. On the
health authority level and senior health plan manage-
ment level planners decide on the specialty and service
mix they wish to purchase for their beneficiaries with
the goal to optimize resource allocation to health
programs. This allocation process is often a mix of
rational thinking and a political agenda. In the
increasingly privatized hospital market decisions are
made about the purchase of medicines and equipment
with the goal to maximize profits. At the level of the
individual physicians, prioritization is increasing influ-
enced by medical audits and other forms of peer
review, with more clinical guidelines. These constrains
usually impose the payers view on the economics of
medicines upon individual physicians. This is not to say
that it is generally bad to impose such constrains to the
health delivery system as long as such decisions are
based on solid evidence. Pharmacoeconomics can help
to make better informed choices.
In this respect, economic analyses have become
important tools to help prioritize health care inter-
ventions. The beauty of these analyses is that they
make the economic dimension more explicit. In the
case of rationing health care, cost-effectiveness analy-
ses may be a fairer and more justified approach, than
decision making without empirical evidence. However,
it must be stressed that prioritisation must always be
based on the prior sound establishment of a tech-
nology_s clinical effectiveness and safety. Only there-
after, do economic analyses come into play.
The study by Scuffham & Kosa revealed a cost-
effectiveness ratio of Euro 15910. Even though there
are not yet acknowledged thresholds in Hungary on
the level up to which services should be covered by
payers, it is common understanding that such a value is
well within the range of acceptable cost-utility values
in most European countries. Hence, the treatment of
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post-PCI patients with fluvastatin should represent
good value for money.
Geoffrey Rose [6] the doyen of preventive cardiol-
ogy, stated in 1991 that Fall policy decisions should be
based on absolute measures of risk; relative risk is
strictly for researchers only_. By extrapolation then, risk
management for prevention of coronary heart disease
should be based on absolute global risk assessment, so
that scarce healthcare resources can be targeted at
those patients in greatest need. In this respect, we must
ask ourselves, if the additional investment of fluvastatin
is a worthwhile endeavour. Clearly, Scuffham & Kosa
have given ample evidence that this is the case, not only
in the Hungarian health care setting, but also in other
countries. It is laudable, that these analyses are also
increasingly being compiled not only for economically
advance countries, but also less economically devel-
oped countries around the globe.
In this sense: ad multas copias.
This piece of mind is dedicated to my beloved
father, Dr. Dezso Lajos Szucs (*Budapest 1935–
+Basel 2005), a true Hungarian in heart and soul.
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